Production (Stage)
CervoMed Inc.
CRVO
$7.26
$0.141.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.14% | 36.29% | 116.29% | 208.63% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.14% | 36.29% | 116.29% | 208.63% | -- |
| Cost of Revenue | 128.51% | 131.88% | 169.50% | 193.23% | -- |
| Gross Profit | -1,342.37% | -895.53% | -212.22% | 275.83% | -- |
| SG&A Expenses | 23.22% | 40.61% | 80.71% | 193.28% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.22% | 86.96% | 115.40% | 167.42% | -- |
| Operating Income | -133.09% | -133.29% | -114.74% | -138.78% | -- |
| Income Before Tax | -349.69% | -650.10% | -793.71% | -15.41% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -349.69% | -650.10% | -793.71% | -15.41% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -349.69% | -650.10% | -793.71% | -15.41% | -- |
| EBIT | -133.09% | -133.29% | -114.74% | -138.78% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 25.67% | 43.29% | 73.74% | 95.25% | -- |
| Normalized Basic EPS | 25.67% | 43.29% | 73.74% | 95.25% | -- |
| EPS Diluted | 49.24% | 58.95% | 78.45% | 79.27% | -- |
| Normalized Diluted EPS | 27.65% | 44.54% | 74.08% | 94.31% | -- |
| Average Basic Shares Outstanding | 114.02% | 204.13% | 513.80% | 1,079.89% | -- |
| Average Diluted Shares Outstanding | 108.16% | 191.54% | 460.92% | 1,102.01% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |